Norbert Jost

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Atrial Fibrillation

Venous Thromboembolism

Saccharomyces Cerevisiae

Genetic Diversity

Top Venues

Pharmaceuticals (Basel, Switzerland)

Archives of toxicology

This page only lists publications with an associated author ORCID identifier.

Publications

Márta Ágoston, Zsófia Kohajda, László Virág, Beáta Baláti, Norbert Nagy, Csaba Lengyel, Miklós Bitay, Gábor Bogáts, András Vereckei, Julius Gy Papp, András Varró, Norbert Jost
A Comparative Study of the Rapid (I Kr ) and Slow (I Ks ) Delayed Rectifier Potassium Currents in Undiseased Human, Dog, Rabbit, and Guinea Pig Cardiac Ventricular Preparations. Pharmaceuticals (Basel, Switzerland) 17 (8) (2024)
Márta Ágoston, Zsófia Kohajda, László Virág, Beáta Baláti, Norbert Nagy, Csaba Lengyel, Miklós Bitay, Gábor Bogáts, András Vereckei, Julius Gy Papp, András Varró, Norbert Jost
A Comparative Study of the Rapid (I Kr ) and Slow (I Ks ) Delayed Rectifier Potassium Currents in Undiseased Human, Dog, Rabbit, and Guinea Pig Cardiac Ventricular Preparations. Pharmaceuticals (Basel, Switzerland) 17 (8) (2024)
Muhammad Naveed, Aiman Saleh A Mohammed, Leila Topal, Zsigmond Máté Kovács, Csaba Dienes, József Ovári, Norbert Szentandrássy, János Magyar, Tamas Banyasz, János Prorok, Norbert Jost, László Virág, Istvan Baczko, András Varró, Péter P Nánási, Balázs Horváth
Selective Inhibition of Cardiac Late Na + Current Is Based on Fast Offset Kinetics of the Inhibitor. Biomedicines 11 (9) (2023)
Szilvia Déri, Teodóra Hartai, László Virág, Norbert Jost, Alain J Labro, András Varró, Istvan Baczko, Stanley Nattel, Balázs Ördög
A Possible Explanation for the Low Penetrance of Pathogenic KCNE1 Variants in Long QT Syndrome Type 5. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Szilvia Déri, Teodóra Hartai, László Virág, Norbert Jost, Alain J Labro, András Varró, Istvan Baczko, Stanley Nattel, Balázs Ördög
A Possible Explanation for the Low Penetrance of Pathogenic KCNE1 Variants in Long QT Syndrome Type 5. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Szilvia Déri, Teodóra Hartai, László Virág, Norbert Jost, Alain J Labro, András Varró, Istvan Baczko, Stanley Nattel, Balázs Ördög
A Possible Explanation for the Low Penetrance of Pathogenic KCNE1 Variants in Long QT Syndrome Type 5. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Leila Topal, Muhammad Naveed, Péter Orvos, Bence Pászti, János Prorok, Ákos Bajtel, Tivadar Kiss, Boglárka Csupor-Löffler, Dezső Csupor, István Baczkó, András Varró, László Virág, Norbert Jost
The electrophysiological effects of cannabidiol on action potentials and transmembrane potassium currents in rabbit and dog cardiac ventricular preparations. Archives of toxicology 95 (7) (2021)
Jesús Borrego, Ádám Fehér, Norbert Jost, Gyorgy Panyi, Zoltan Varga, Ferenc Papp
Peptide Inhibitors of Kv1.5: An Option for the Treatment of Atrial Fibrillation. Pharmaceuticals (Basel, Switzerland) 14 (12) (2021)
Norbert Jost, Torsten Christ, János Magyar
New Strategies for the Treatment of Atrial Fibrillation. Pharmaceuticals (Basel, Switzerland) 14 (9) (2021)